LumiraDx Limited (LMDX): Price and Financial Metrics

LumiraDx Limited (LMDX): $3.72

-0.14 (-3.63%)

POWR Rating

Component Grades













LMDX Stock Price Chart Interactive Chart >

Price chart for LMDX

LMDX Price/Volume Stats

Current price $3.72 52-week high $11.09
Prev. close $3.86 52-week low $3.40
Day low $3.50 Volume 112,100
Day high $3.95 Avg. volume 60,381
50-day MA $5.53 Dividend yield N/A
200-day MA $0.00 Market Cap 168.29M

LumiraDx Limited (LMDX) Company Bio

LumiraDx Limited operates as a point of care diagnostic company. It focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. The company was formerly known as Point of Care Testing Limited and changed its name to LumiraDx Ltd in January 2018. LumiraDx Limited was incorporated in 2002 and is based in London, the United Kingdom.

LMDX Latest News Stream

Event/Time News Detail
Loading, please wait...

LMDX Latest Social Stream

Loading social stream, please wait...

View Full LMDX Social Stream

Latest LMDX News From Around the Web

Below are the latest news stories about LumiraDx Ltd that investors may wish to consider to help them evaluate LMDX as an investment opportunity.

Wall Street Analysts Believe LumiraDx Limited (LMDX) Could Rally 54%: Here's is How to Trade

The mean of analysts' price targets for LumiraDx Limited (LMDX) points to a 53.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | January 25, 2022

Is Community Health Systems (CYH) Outperforming Other Medical Stocks This Year?

Here is how Community Health Systems (CYH) and LumiraDx Limited (LMDX) have performed compared to their sector so far this year.

Yahoo | January 25, 2022

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live Omicron virus demonstrated that the LumiraDx SARS-CoV-2 Antigen test detects the Omicron variant with comparable sensitivity to other variants. In the original U.S. Food and Drug Administration ("FDA") Emergency Use Authorization ("EUA") clini

Yahoo | January 14, 2022

LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.

Yahoo | January 11, 2022

LumiraDx CRP Test Achieves CE Marking

LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced its C-reactive protein (CRP) Test has achieved CE Marking. The LumiraDx CRP Test is a small, portable, fully automated, microfluidic immunoassay test used for the quantitative determination of C-reactive protein with results within four minutes. The measurement of CRP provides important information for the detection and evaluation of infection, and inflammation. In patients with respiratory infection sy

Yahoo | January 11, 2022

Read More 'LMDX' Stories Here

LMDX Price Returns

1-mo -14.48%
3-mo -51.05%
6-mo -64.06%
1-year N/A
3-year N/A
5-year N/A
YTD -58.25%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6344 seconds.